Arcus Biosciences

RCUS · NYSE

$23.75+$1.61 (+7.27%)TodayMarket closed · Oct 20, 7:55 PM ET

Prev close $22.14

Latest news

Press releaseOct 20, 8:30 AM ETBusiness Wire
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
Press releaseOct 9, 4:35 PM ETBusiness Wire
Arcus Biosciences Announces New Employment Inducement Grants
Press releaseSep 24, 4:35 PM ETBusiness Wire
Arcus Biosciences Announces New Employment Inducement Grants
Press releaseSep 22, 8:30 AM ETBusiness Wire
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Press releaseSep 9, 4:35 PM ETBusiness Wire
Arcus Biosciences Announces New Employment Inducement Grants
Press releaseAug 26, 4:05 PM ETBusiness Wire
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
Press releaseAug 19, 7:58 PM ETPRNewswire
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
Press releaseAug 11, 4:35 PM ETBusiness Wire
Arcus Biosciences Announces New Employment Inducement Grants
NewsAug 5, 4:08 PM ET
Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate
Press releaseAug 5, 4:05 PM ETBusiness Wire
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Press releaseJul 27, 4:35 PM ETBusiness Wire
Arcus Biosciences Announces New Employment Inducement Grants
Press releaseJul 22, 4:35 PM ETBusiness Wire
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
Press releaseJul 22, 4:30 PM ETBusiness Wire
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Press releaseJul 22, 4:30 PM ETBusiness Wire
Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Press releaseJul 21, 4:05 PM ETBusiness Wire
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
NewsJul 20, 2:45 PM ETVandana Singh
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?
Press releaseJul 9, 4:35 PM ETBusiness Wire
Arcus Biosciences Announces New Employment Inducement Grants
Press releaseJul 1, 11:00 AM ETBusiness Wire
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
Press releaseJun 24, 4:35 PM ETBusiness Wire
Arcus Biosciences Announces New Employment Inducement Grants
Press releaseJun 9, 4:35 PM ETBusiness Wire
Arcus Biosciences Announces New Employment Inducement Grants
Press releaseJun 3, 8:00 AM ETBusiness Wire
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
Press releaseMay 26, 4:05 PM ETBusiness Wire
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Press releaseMay 5, 4:05 PM ETBusiness Wire
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
NewsMay 5, 7:12 AM ET
Earnings Scheduled For May 5, 2026
Press releaseApr 24, 4:05 PM ETBusiness Wire
Arcus Biosciences Announces New Employment Inducement Grants
NewsApr 22, 3:19 PM ETVandana Singh
What's Going On With Arcus Biosciences Stock On Wednesday?
Press releaseApr 21, 4:05 PM ETBusiness Wire
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
Press releaseApr 9, 4:35 PM ETBusiness Wire
Arcus Biosciences Announces New Employment Inducement Grants
Press releaseMar 24, 4:35 PM ETBusiness Wire
Arcus Biosciences Announces New Employment Inducement Grants
NewsMar 2, 7:00 AM ET
The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts
NewsFeb 25, 4:14 PM ET
Arcus Biosciences Earnings Review: Q4 Summary
Press releaseFeb 25, 4:05 PM ETBusiness Wire
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
NewsFeb 25, 6:11 AM ET
Earnings Scheduled For February 25, 2026
NewsFeb 12, 9:00 AM ET
What Analysts Are Saying About Arcus Biosciences Stock
NewsDec 12, 1:35 PM ETVandana Singh
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
NewsNov 25, 8:01 AM ETAvi Kapoor
Semtech Posts Mixed Q3 Results, Joins Zhihu, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
NewsNov 25, 5:50 AM ETAvi Kapoor
Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
NewsNov 23, 4:28 PM ETGianni di Poce
The Insider Report: Prepare for the Next Dip Buying Opportunity
NewsOct 29, 7:45 AM ET
Analyst Expectations For Arcus Biosciences's Future
NewsAug 8, 10:55 AM ETVandana Singh
Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears
NewsApr 23, 9:00 AM ET
Forecasting The Future: 5 Analyst Projections For Arcus Biosciences

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate

Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates

Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?

Arcus Biosciences Announces New Employment Inducement Grants

New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

Earnings Scheduled For May 5, 2026

Arcus Biosciences Announces New Employment Inducement Grants

What's Going On With Arcus Biosciences Stock On Wednesday?

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts

Arcus Biosciences Earnings Review: Q4 Summary

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

Earnings Scheduled For February 25, 2026

What Analysts Are Saying About Arcus Biosciences Stock

Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug

Semtech Posts Mixed Q3 Results, Joins Zhihu, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Why Keysight Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

The Insider Report: Prepare for the Next Dip Buying Opportunity

Analyst Expectations For Arcus Biosciences's Future

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Forecasting The Future: 5 Analyst Projections For Arcus Biosciences